An interventional study of Group A and Group B in Diabete Mellitus, sponsored by Emad Eldin Mohamed. Active, not recruiting at 1 site in Egypt. Open to participants aged 50 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Emad Eldin Mohamed · Not applicable, Interventional, and Treatment
Type 2 diabetes mellitus (T2DM) is strongly associated with an increased risk of cognitive impairment via multiple, converging pathways chronic hyperglycemia, insulin resistance, and vascular injury leading to deficits in memory, attention, and executive functions. Large-scale reviews and epidemiologic syntheses note high prevalence of mild cognitive impairment (MCI) in diabetes and underscore the need for targeted interventions that address metabolic and neurocognitive mechanisms simultaneously.
Type 2 diabetes mellitus (T2DM) is strongly associated with an increased risk of cognitive impairment via multiple, converging pathways chronic hyperglycemia, insulin resistance, and vascular injury leading to deficits in memory, attention, and executive functions. Large-scale reviews and epidemiologic syntheses note high prevalence of mild cognitive impairment (MCI) in diabetes and underscore the need for targeted interventions that address metabolic and neurocognitive mechanisms simultaneously.
Periodontal disease is common in T2DM and has a bidirectional relationship with glycemic control. Randomized trials and meta-analyses show that non-surgical periodontal therapy (NSPT), especially scaling and root planning (SRP), can reduce HbA1c and improve periodontal indices; several syntheses also report short-term reductions in systemic inflammatory biomarkers such as high-sensitivity C-reactive protein. Concurrently, longitudinal and systematic reviews suggest an association between poor periodontal health and cognition impairment through chronic inflammation, bacterial transmission to the brain, and reduction of nutrient intake, increasing the risk of dementia. Harmful bacteria, such as Porphyromonas gingivalis, can enter the bloodstream and travel to the brain, contributing to plaque build-up and neurodegeneration
11,089 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.
This study's enrollment of 105 is above the median of 80 across 8,491 interventional studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →Emad Eldin Mohamed is the lead sponsor of 5 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
* Adaptive cognitive training (memory, attention, processing speed, executive functions). * Dosage: 2 sessions per week/60 minutes per session.
Other: Group A
* Curettes and scalers used to remove plaque and tartar (calculus) from tooth surfaces. Scalers are used for supra-gingival (above gum line) cleaning, while curettes feature a rounded toe for safe, effective sub-gingival (below gum line) scaling, root planning, and tissue removal * Dosage: 2 sessions per week/60 minutes per session. * Aerobic: 20 min. * Balance: 10 min (tandem stance and dynamic weight shifts). * Resistance (elastic bands): 15 min, 2sets with 10 reps for major muscle groups; progress band color/resistance every 2 weeks.
Other: Group B
combination programme of each group
Other: Group C
multimodal cognitive rehabilitation alone
• Curettes and scalers
multimodal cognitive rehabilitation in combination with mechanical periodontal therapy
1- Montreal Cognitive Assessment test (MoCA)
MoCA used for measurement of Global cognition (memory, attention, language, and visuospatial skills, with a score of 26 or higher considered normal)
Time frame: 12 weeks
2- Trail Making Test (TMT) Part A and B
TMT used for measurement of executive function which consists of two parts, A and B. The participant will need a pencil to perform each part.
Time frame: 12 Weeks
3- Symbol Digit Modalities Test (SDMT)
SDMT used to assess information processing speed, visual scanning, tracking, and motor speed. The participants match 9 geometric symbols with corresponding digits (1-9) using a key. Participants write or speak the correct number for each symbol in a randomized sequence for 90 seconds.
Time frame: 12 weeks
4- The HbA1c test
The HbA1c test measures average blood sugar levels over the past 2-3 months via a simple blood draw from a vein (or occasionally a finger prick). No fasting or special preparation is required
Time frame: 12 weeks
5- A C-Reactive Protein (CRP)
CRP measures the inflammation levels in the body by collecting blood from a vein in the arm
Time frame: 12 weeks
6- Oral Health-Related Quality of Life (OHRQoL)
OHRQoL used to measure the functional, social, and psychological impacts of oral conditions. Instructions require patients to rate the frequency or severity of issues (e.g., pain, chewing difficulty) over a specific period, often using Likert scales (e.g., "never" to "very often" or "always" to "never")
Time frame: 12 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Oct 2026, 8 months after the start.
Of 2,196 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 38. This study's planned 8 months is below that.
Counting every sponsor, half of 2,388 studies reached it within 20 months; a quarter within 9 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Emad Eldin Mohamed